- The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD
- The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%
- The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension
- Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) has been published in eight peer-reviewed articles across six different publications. Lexaria’s research into DehydraTECH-CBD is being considered for indications including hypertension, diabetes, epilepsy, and more. Hypertension, heart disease, and diabetes are broad fields of interest for the company, with DehydraTECH-CBD generating positive pilot-study data.
“We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://cnw.fm/U97ZK). “Lexaria is establishing itself as one of…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
[email protected]
CBDWire is part of the InvestorBrandNetwork.